Merit Medical Systems INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Merit Medical Systems Inc. announced a 9.5% increase in net sales for the second quarter of 2026, driven by growth in both foundational and therapeutic product categories.
NASDAQ
Merit Medical Systems, Inc. reported increased net sales and gross profit for Q3 2025, alongside a CEO transition and the conclusion of an SEC inquiry.
NASDAQ
Merit Medical Systems reports increased net sales for Q2 2025 driven by acquisitions and international demand, but net income and EPS declined due to higher operating expenses and tax rates.
NASDAQ
Merit Medical Systems reports a 9.8% increase in revenue and a rise in net income for the first quarter of 2025, driven by strong U.S. demand and strategic acquisitions.
NASDAQ
10-Q: Merit Medical Systems Reports Strong Q3 2024 Results, Driven by U.S. and International Sales Growth
Merit Medical Systems, Inc. announced a 7.8% increase in sales for the third quarter of 2024, reaching $339.8 million, alongside a rise in net income to $28.4 million.
NASDAQ
10-Q: Merit Medical Systems Reports Strong Second Quarter Growth Driven by U.S. and International Sales
Merit Medical Systems, Inc. announced a 7.1% increase in sales for the six-month period ended June 30, 2024, driven by strong U.S. and international demand.
NASDAQ
10-Q: Merit Medical Systems Reports Strong Q1 2024 Results Driven by U.S. and International Sales Growth
Merit Medical Systems reported an 8.7% increase in net sales for the first quarter of 2024, driven by strong U.S. and international demand.